You are here

Generic Sarafem Receives FDA Nod

PITTSBURGH, Aug. 30 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Fluoxetine Capsules, USP, 10mg and 20mg.

Fluoxetine Capsules are indicated for the treatment of premenstrual dysphoric disorder (PMDD). They are the AB-rated generic version of Eli Lilly and Company's Sarafem Pulvules Capsules, which had annual U.S. sales of approximately $52 million for the 12 months ending June 30, 2006.

Source: Mylan Laboratories

Recent Headlines

Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
One in Five Kids’ Office Visits Results in an Off-Label Rx
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds